共 50 条
- [1] Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast: Subset Analysis of Patients With Scalp Psoriasis in the Phase 3 POETYK PSO-1 and POETYK PSO-2 TrialsJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 25 - 25Thaci, DiamantRich, PhoebeSofen, HowardMerola, JosephStrober, BruceMorita, AkimichiSzepietowski, JacekColston, ElizabethThroup, JohnWang, TaoBanerjee, SubhashisBlauvelt, Andrew
- [4] Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Achievement of Absolute PASI Thresholds in the Phase 3 POETYK PSO-1 and PSO-2 TrialsJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 119 - 120Thaci, DiamantLebwohl, MarkGooderham, MelindaWarren, Richard B.Foley, PeterGottlieb, Alice B.Banerjee, SubhashisHippeli, LaurenKisa, RenataGriffiths, Christopher
- [5] Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: Achievement of absolute PASI thresholds in the phase 3 POETYK PSO-1 and PSO-2 trialsJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB41 - AB41Lebwohl, MarkGooderham, MelindaWarren, Richard B.
- [6] Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in psoriasis: Reductions in individual component scores and body regions of the Psoriasis Area and Severity Index in the phase 3 POETYK PSO-1 and PSO-2 trialsJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB41 - AB41Sobell, Jeffrey M.Eyerich, KilianBlauvelt, Andrew
- [7] Deucravacitinib (DEUC), an Oral, Selective Tyrosine Kinase 2 ( TYK2) Inhibitor, Versus Placebo (PBO) and Apremilast (APR) in Moderate to Severe Plaque Psoriasis: Safety Analysis by Prior Therapy Subgroups in the Phase 3 POETYK PSO-1 and PSO-2 TrialsJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 120 - 120Eyerich, KilianWarren, Richard B.Blauvelt, AndrewGudjonsson, JohannSobell, JeffreyBanerjee, SubhashisBalagula, EugeneHippeli, LaurenGooderham, Melinda
- [8] Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis who had inadequate responses to apremilast at week 24 in the phase 3 POETYK PSO-1 and PSO-2 trialsJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB156 - AB156Armstrong, April W.Warren, Richard B.Sofen, HowardSpelman, LyndaLeonardi, CraigBanerjee, SubhashisWang, TaoThroup, JohnColston, ElizabethNapoli, AndrewKimball, Alexa B.
- [10] Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK PSO-1 and PSO-2 trialsAUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 51 - 51Eisman, SamanthaBlauvelt, AndrewRich, PhoebeSofen, HowardLambert, JoMerola, JosephLebwohl, MarkScharnitz, ThomasHoyt, KimKisa, Renata M.Banerjee, Subhashis